Exudate

ExtriCARE USA Introduces the ExtriCARE 1000 NPWT System

Retrieved on: 
Tuesday, March 19, 2024
Philosophy, Patient, Certification, FDA, Exudate, CE, NPWT, Mobility

NORRISTOWN, Pa., March 19, 2024 /PRNewswire/ -- ExtriCARE USA, a leader in advanced wound care solutions, proudly announces the launch of the ExtriCARE 1000 Negative Pressure Wound Therapy (NPWT) System.

Key Points: 
  • NORRISTOWN, Pa., March 19, 2024 /PRNewswire/ -- ExtriCARE USA, a leader in advanced wound care solutions, proudly announces the launch of the ExtriCARE 1000 Negative Pressure Wound Therapy (NPWT) System.
  • The ExtriCARE 1000 sets a new standard in wound care therapy with its tailored approach.
  • Designed for patient comfort and mobility, the ExtriCARE 1000 is compact and lightweight, weighing just 0.5 lbs., facilitating ease of use in various care settings.
  • The ExtriCARE 1000 offers versatility and utilizes ExtriCARE's hybrid NPWT (hNPWT) philosophy.

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

Retrieved on: 
Tuesday, December 5, 2023
Health, Communications, Clinical Trials, Pharmaceutical, Publishing, Optical, Biotechnology, Yoshi, Intravitreal injection, Safety, Visual acuity, Retina, Royal college, Anatomy, Risk, Exudate, Anti-VEGF, FGF2, Patient, P, Choroidal neovascularization, Aptamer, Eye, Therapy, Blood, Growth factor, Royal College of Ophthalmologists, Paratriathlon, NAMD, SUSHI, Fibrosis, Pharmaceutical industry, D.S

TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.

Key Points: 
  • TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.
  • Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment.
  • In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®.
  • Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study.

Medela Expands Negative Pressure Wound Therapy Product Solutions with New Integrated Dressing

Retrieved on: 
Tuesday, August 15, 2023
Pressure, Education, NPWT, Exudate, Patient, Control, Integration, FDA, Intelligence, Environment, Conference, Wound healing, Nursing

The Invia® Integrated Dressing is indicated for all wound types, including closed surgical incision, and can be used in the hospital or home setting, for up to seven days.

Key Points: 
  • The Invia® Integrated Dressing is indicated for all wound types, including closed surgical incision, and can be used in the hospital or home setting, for up to seven days.
  • “We are thrilled to support the needs of our customers across the USA by introducing our Integrated Dressing,” explains Annette Brüls, CEO of Medela.
  • The Integrated Dressing is a ‘peel-and-stick’ adhesive, comprised of a three-layer fluid handling pad that features a skin-friendly silicone adhesive border.
  • To learn more about Medela’s complete negative wound pressure therapy system, visit medelahealthcare.com or fill out the online form to receive information, or visit the Medela booth at the SAWC Fall Conference in November in Las Vegas.

TAICEND's World-leading Hydrophilic Polyurethane Foam Technology

Retrieved on: 
Friday, January 27, 2023
Foam, National Cheng Kung University, Water, Inflammation, Hydrophile, Exudate, Rehabilitation, National Cheng Kung University Hospital, Exhibition, Polyurethane, Risk, Infection, MVTA, Breathability, Maharashtra University of Health Sciences, Wood-plastic composite

DALLAS, Jan. 27, 2023 /PRNewswire/ -- TAICEND's world-leading Hydrophilic Polyurethane Foam Technology is a patented, exclusive material that has demonstrated high safety and effectiveness in the medical field.

Key Points: 
  • DALLAS, Jan. 27, 2023 /PRNewswire/ -- TAICEND's world-leading Hydrophilic Polyurethane Foam Technology is a patented, exclusive material that has demonstrated high safety and effectiveness in the medical field.
  • As stated above, TAICEND's Hydrophilic PU Foam has an exceptionally high absorption rate, found to have a representative value of 900% following the testing method EN 13726-1.
  • Water is attracted to the molecular composition of the hydrophilic PU Foam, which gives it a high water retention rate.
  • This is why TAICEND's Hydrophilic Polyurethane Foam Technology is an ideal choice for any medical professional.

Clinical Pilot Study Published in Journal of Wound Care Looks at a Better Solution for Surgical Site Dressings

Retrieved on: 
Wednesday, October 5, 2022
Surgery, Infectious Diseases, Health, Health Technology, Medical Supplies, CDC, Color, Growth, Infection, SSIS, Patient, Technology, Trial of the century, Exudate, Water, Journal, Compliance, Bandage, Medicine

DrySee was the focus of a new clinical study published in the September issue of Journal of Wound Care .

Key Points: 
  • DrySee was the focus of a new clinical study published in the September issue of Journal of Wound Care .
  • Results concluded that compared to gauze or a 3M Tegaderm + Pad transparent film dressing, 75% of patients preferred the DrySee wound dressing.
  • The DrySee dressing also had a greater wear time and patients reported that it stayed in place better during activities.
  • DrySee wound coverings have many uses, but the study was acutely focused on the potential to reduce surgical site infections (SSIs).

Global Acne Treatment Market Report to 2027 - Featuring Galderma, Lumenis, Cutera and Alma Lasers Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 26, 2022
Health, Other Health, Adoption, Inflammation, Incidence, Efficiency, Retinoid, Exudate, Exocrine gland, Social stigma, Acne, Dust, Company, Market share, Environment, Formulation, Skin, CAGR, Sulfur

The global acne treatment market is projected to grow at an impressive CAGR in the forecast period, 2023-2027.

Key Points: 
  • The global acne treatment market is projected to grow at an impressive CAGR in the forecast period, 2023-2027.
  • Factors such as severe social stigma associated with acne, growing public knowledge of cosmetic acne treatments, and increased accessibility of these treatments are driving the demand for the global Acne Treatment Market.
  • The global acne treatment market is segmented into therapeutic class, formulation, type, acne type, distribution channel, regional distribution, and competitive landscape.
  • Based on acne type, the market is divided into cystic acne, postsurgical/wound acne, comedonal acne, and inflammatory acne.

Smith+Nephew launches Clinical Support App to help reduce practice variation in wound care

Retrieved on: 
Tuesday, July 12, 2022
Technology, Smith & Nephew, Group, U.S. Securities and Exchange Commission, Multimedia, Formulary, Pulitzer Prize for International Reporting, ENT, Apple, Exudate, United States Patent and Trademark Office, LinkedIn, Phrase, View, Digital health, Android, Instagram, Patent, FTSE100, Regeneration, International, Longevity, Sports medicine, Unlimited, United States patent law, Forward-looking statement, Failure, Annual report, SNN, Twitter, LSE, NYSE, Form 20-F, Medicine, Medical device, Pharmaceutical industry, Facebook, COVID-19

The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.

Key Points: 
  • The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.
  • With limited wound care education and experience, this has contributed to significant challenges with practice variation.
  • The WOUND COMPASS Clinical Support App has been piloted and validated with more than 70 clinicians through more than 400 assessments.
  • World Union of Wound Healing Societies (2020) Strategies to reduce practice variation in wound assessment and management: The T.I.M.E.

Smith+Nephew launches Clinical Support App to help reduce practice variation in wound care

Retrieved on: 
Tuesday, July 12, 2022
Technology, Smith & Nephew, Group, U.S. Securities and Exchange Commission, Formulary, Pulitzer Prize for International Reporting, ENT, Apple, Exudate, United States Patent and Trademark Office, LinkedIn, Phrase, Digital health, Android, Instagram, Patent, FTSE100, Regeneration, International, Longevity, Sports medicine, Unlimited, United States patent law, Forward-looking statement, Failure, Annual report, SNN, Twitter, LSE, NYSE, Form 20-F, Medicine, Medical device, Pharmaceutical industry, Facebook, COVID-19

The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.

Key Points: 
  • The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.
  • With limited wound care education and experience, this has contributed to significant challenges with practice variation.
  • The WOUND COMPASS Clinical Support App has been piloted and validated with more than 70 clinicians through more than 400 assessments.
  • World Union of Wound Healing Societies (2020) Strategies to reduce practice variation in wound assessment and management: The T.I.M.E.

Vial Adds Dr. Jeffrey Heier of OCB to their Ophthalmology CRO Advisory Board

Retrieved on: 
Tuesday, July 12, 2022
SAB, SAN, OCB, Traction, Neurology, Boston, CTMS, EMR, ESourcing Capability Model, Vial, Boston University, Gastroenterology, Marketing, Exudate, Society, Therapy, Fitzsimons Army Medical Center, S-1 Executive Committee, Medical director, Multimedia, Executive Committee, Technology, CRO, Thrombosis, Research, Disease, Diabetic retinopathy, Google Images, Veterinary medicine, Medical device, Dermatology, Retina, Ophthalmology

SAN FRANCISCO, July 11, 2022 /PRNewswire/ --Dr. Jeffrey Heier, from Ophthalmic Consultants of Boston (OCB) has joined Vial's Ophthalmology Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO, July 11, 2022 /PRNewswire/ --Dr. Jeffrey Heier, from Ophthalmic Consultants of Boston (OCB) has joined Vial's Ophthalmology Scientific Advisory Board.
  • Dr. Heier joins the Vial SAB alongside the SAB founding board member, Dr. Arshad Khanani, to advise Vial on the launch of their upcoming Ophthalmology CRO.
  • The Vial CRO strives to be a true partner to biotech companies by delivering faster and higher quality trials through a powerful technology platform and operational excellence.
  • "I have devoted my career to the development of innovative Ophthalmic treatments and I joined the Vial CRO advisory board to continue pursuing that mission.

Medline introduces enhanced Optifoam Gentle EX foam dressing to help pressure injury prevention

Retrieved on: 
Friday, June 3, 2022
Foam, Transfer, Consensus, Mouth ulcer, Friction, Pressure, Health risk assessment, Trauma, WOC, Solution, Skin, Exudate, Transformer, Asphalt, Medicine, MEDLINE

NORTHFIELD, Ill., June 2, 2022 /PRNewswire/ -- Medline today announced a new version of its Optifoam® Gentle EX Foam Dressing. Updated to help reduce pressure injuries, the company will debut the product in-person at booth #511 during the 2022 WOCNext conference in Fort Worth, Texas, from June 5-8. Medline's Optifoam Gentle EX dressing is a key product in the company's Skin Health Solution Program, a holistic approach to skin and wound care focused on people, process and products.

Key Points: 
  • NORTHFIELD, Ill., June 2, 2022 /PRNewswire/ -- Medline today announced a new version of its Optifoam Gentle EX Foam Dressing .
  • Medline's Optifoam Gentle EX dressing is a key product in the company's Skin Health Solution Program , a holistic approach to skin and wound care focused on people, process and products.
  • Medline's Optifoam Gentle EX is designed to help displace pressure when used with pressure injury prevention protocol.
  • The product features five unique layers to help absorb shear force and friction and manage moisture:
    Silicone layer minimizes trauma to the wound with gentle adhesion.